Clinical Research Directory
Browse clinical research sites, groups, and studies.
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Sponsor: Novo Nordisk A/S
Summary
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.
Official title: Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-04-10
Completion Date
2028-06-09
Last Updated
2026-05-07
Healthy Volunteers
No
Conditions
Interventions
Cagrilintide
Participants will receive cagrilintide subcutaneously.
Semaglutide
Participants will receive semaglutide subcutaneously.
Placebo cagrilintide
Participants will receive placebo matched to cagrilintide subcutaneously.
Placebo semaglutide
Participants will receive placebo matched to semaglutide subcutaneously.
Locations (1)
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus N, Denmark